Report Overview

The EU Pulmonary arterial hypertension market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Pulmonary arterial hypertension (PAH) is a form of condition known as pulmonary hypertension which means high level blood pressure in the lungs. PAH is characterized by an increase in pressure within the pulmonary arteries because of structural changes within vessel walls, aggregation of platelets and alteration of swish somatic cell function resulting into increasing pressure within the pulmonic arteries chargeable for pumping blood to the lungs. Change in routine of consumers in terms of lack of physical activity and more consumption of alcohol, tobacco, and fast food products increases the chances of developing hypertension and high blood pressure. The increased blood pressure in turn, gives rise to several diseases such as stroke and heart attacks. Treatment of pulmonary arterial hypertension can be done by using drugs such as endothelin receptor antagonists, prostacyclin and prostacyclin analogs, soluble guanylate cyclase stimulators, and phosphodiesterase type 5 inhibitor



 

Market Drivers

Increase in consumption of alcohol or tobacco, sedentary lifestyle, smoking, & other idiopathic conditions, increase in geriatric population, and increase in adoption of treatment & healthcare spending are the factors that drive the growth of the pulmonary arterial hypertension market